Day 2 – Wednesday, 17 Sept 2025Wednesday, September 17, 2025 - ET (Eastern Time, GMT-05:00)

In an increasingly complex funding landscape, biotech companies face unprecedented challenges in maximizing asset value while building sustainable organizational foundations. This timely panel brings together industry veterans who have successfully navigated market volatility to share practical strategies for commercial optimization and organizational resilience. As investor expectations evolve and partnership models transform, executives must balance immediate commercial imperatives with long-term capability building to ensure continued growth and innovation.

• Maximizing Asset Value in Capital-Constrained Markets – Innovative approaches to demonstrate and enhance value when traditional funding channels tighten.
• Embedding Commercial Thinking Early – How commercial considerations in early development create differentiated assets and prevent costly late-stage pivots.
• Build vs. Partner: Finding the Right Balance – Strategic decisions on when to develop internal capabilities versus leveraging external partnerships for commercial success.
• Future-Proofing Commercial Strategy – Creating adaptable commercial frameworks that can evolve with changing market dynamics and stakeholder expectations.

• Reviewing the impact of the obesity therapeutics on consumer behaviour
• Discussing future changes to the food industry as anti-obesity drugs progress, from ingredient sourcing to retail dynamics